Philippe Jacqmin
85 works · 2,223 citations · h-index 22
Top works
- Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
- OP0204 EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)
- Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model
- Repeated-Dose Pharmacokinetics of an Oral Solution of Itraconazole in Infants and Children
- Efficacy and safety of emapalumab in macrophage activation syndrome
- A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
- A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis
- Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
- A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
- Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence
- Retrospective Population Pharmacokinetic Analysis of Levetiracetam in Children and??Adolescents with Epilepsy
- The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
- Population Pharmacokinetics of??Levetiracetam in Japanese and??Western Adults
- Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR‐SOB Scores From ADNI
- Population pharmacokinetic/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV‐positive patients
- Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects
- A Combined Specific Target Site Binding and Pharmacokinetic Model to Explore the Non-linear Disposition of Draflazine
- Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules
- Evidence of NI‐0101 pharmacological activity, an anti‐TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS
- Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin